

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 20, 2024**

**DAY ONE BIOPHARMACEUTICALS, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-40431**  
(Commission  
File Number)

**83-2415215**  
(IRS Employer  
Identification No.)

**2000 Sierra Point Parkway, Suite 501**  
**Brisbane, California**  
(Address of principal executive offices)

**94005**  
(Zip Code)

**Registrant's telephone number, including area code: (650) 484-0899**

**N/A**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	DAWN	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On November 20, 2024, Samuel Blackman, M.D., Ph.D, notified Day One Biopharmaceuticals, Inc. (the “Company”) of his intention to retire from his position as Head of Research & Development of the Company effective at the end of 2024. Dr. Blackman is a co-founder of the Company and has served as the Company’s Head of Research & Development since May 2023 and previously served as the Company’s Chief Medical Officer from the Company’s founding. Dr. Blackman will continue to serve as a strategic advisor and consultant while the Company seeks a new Head of Research & Development.

The Company extends its gratitude to Dr. Blackman for his years of service and contributions to the Company.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**DAY ONE BIOPHARMACEUTICALS, INC.**

Date: November 20, 2024

By: /s/ Charles N. York II, M.B.A.  
Charles N. York II, M.B.A.  
Chief Operating Officer and Chief Financial Officer